-


Thyroid in balance: why selenium and zinc matter
The thyroid: small gland, big job

Drives metabolism, temperature and energy.

Imbalance may show up as:

Hypothyroidism → sluggish metabolism, fatigue, weight gain.

Hyperthyroidism → racing heart, weight loss, anxiety.

Research links many thyroid issues to micronutrient gaps.

Two trace minerals you can’t ignore


Selenium

Builds antioxidant enzymes that defend thyroid cells.

Converts inactive T4 to active T3 hormone.

Zinc

Assists hormone production and immune regulation.

Clinical data: low selenium or zinc correlates with slower metabolic rate and poorer hormone balance.

Easy ways to raise your levels

Food first

brazil nuts (selenium), seafood and eggs (selenium + zinc), pumpkin seeds (zinc).

Smart supplementation

Look for a daily capsule providing ~200 µg selenium + 10 mg zinc in bioavailable forms.

Lifestyle checks

Manage stress and prioritise sleep; cortisol can disrupt thyroid conversion.

Evidence corner

European Thyroid Association – Trace Elements and Thyroid

NIH – Selenium Fact Sheet

Harvard Health – The Thyroid and Your Body

Quick takeaway


Balanced thyroid = sufficient selenium, adequate zinc, and consistent healthy habits. Check your nutrient intake, top up if needed, and keep your metabolism humming. https://healthpont.com/thyroid-selenium-zinc/

Comments

Post a Comment

Popular posts from this blog

-
Image
In today’s fast-paced world, carving out time for lengthy workouts can be difficult. That’s one reason short workouts – sometimes just 10 or 15 minutes long – have become increasingly popular. But do these “exercise snacks” actually work? The short answer: yes. According to a growing body of research, short, intense bouts of physical activity can deliver impressive health benefits – helping you get fitter, live longer, and feel better. Backed by Research Studies show that you don’t need long gym sessions to improve your health. A 2023 study published in the European Heart Journal found that just 15 minutes of vigorous exercise per week – broken into two-minute bouts – was associated with a 40% lower risk of heart disease, 16% lower risk of cancer, and an 18% reduced risk of death from any cause. (Source) Similarly, research published in JAMA Internal Medicine supports the idea that short bursts of physical activity, even from daily tasks like climbing stairs or fast-paced walking...
Read more
-
Image
Erectile dysfunction (ED) is far more common than most men realise — and it’s not just a matter of ageing. It’s often a sign of underlying vascular, hormonal, or emotional imbalances. The good news? ED is treatable in the majority of cases. But choosing the right therapy is essential — and it should always be done safely, under medical guidance. The main treatment options Across Europe, the first-line treatment for ED usually involves medicines known as PDE5 inhibitors. These drugs improve blood flow to the penis by relaxing the muscles of the blood vessels — helping to achieve and maintain an erection during sexual arousal. They are not stimulants and they do not cause automatic erections. Rather, they support the body’s natural physiological response when sexual stimulation is present. Different options within this group may vary in: - How fast they start working (from 15 to 60 minutes) - How long the effect lasts - How they interact with food or other medications Y...
Read more
-
Ο EMA (Ευρωπαϊκός Οργανισμός Φαρμάκων) ανακοίνωσε ότι η αναστολή της άδειας κυκλοφορίας του φαρμάκου Oxbryta, για τη δρεπανοκυτταρική νόσο, θα παραμείνει σε ισχύ.Με βάση την αξιολόγηση νέων δεδομένων, η επιτροπή CHMP κατέληξε ότι τα οφέλη του φαρμάκου δεν υπερτερούν πλέον των κινδύνων. Οι πρόσφατες κλινικές μελέτες έδειξαν αυξημένο αριθμό θανάτων και περισσότερα επεισόδια ξαφνικού και έντονου πόνου σε ασθενείς που έλαβαν Oxbryta σε σύγκριση με placebo. Καθώς οι μηχανισμοί που οδηγούν σε αυτές τις επιπλοκές παραμένουν ασαφείς και δεν υπάρχουν μέτρα για τη μείωση του κινδύνου, ο EMA αποφάσισε ότι το φάρμακο δεν μπορεί να συνεχίσει να χρησιμοποιείται. Το Oxbryta παραμένει μη διαθέσιμο για συνταγογράφηση στην ΕΕ. Δείτε την επίσημη ανακοίνωση του EMA στα αγγλικά εδώ https://vitadaily.gr/o-ema-diatirei-tin-anastoli-kykloforias-tou-oxbryta-stin-ee/
Read more